There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on SAGE Therapeutics (SAGE – Research Report), Poseida Therapeutics (PSTX – Research Report) and Align Tech (ALGN – Research Report) with bullish sentiments.
SAGE Therapeutics (SAGE)
In a report released today, George Farmer from Scotiabank maintained a Buy rating on SAGE Therapeutics, with a price target of $19.00. The company’s shares closed last Wednesday at $12.57, close to its 52-week low of $10.92.
According to TipRanks.com, Farmer is a 4-star analyst with an average return of
SAGE Therapeutics has an analyst consensus of Hold, with a price target consensus of $21.79, implying a 68.1% upside from current levels. In a report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $16.00 price target.
See the top stocks recommended by analysts >>
Poseida Therapeutics (PSTX)
Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Poseida Therapeutics today and set a price target of $10.00. The company’s shares closed last Wednesday at $2.04.
According to TipRanks.com, Tenthoff is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Poseida Therapeutics with a $14.00 average price target, which is a 589.7% upside from current levels. In a report issued on April 8, William Blair also maintained a Buy rating on the stock.
Align Tech (ALGN)
In a report released today, Jason Bednar from Piper Sandler maintained a Buy rating on Align Tech, with a price target of $355.00. The company’s shares closed last Wednesday at $300.14.
According to TipRanks.com, Bednar is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Align Tech with a $308.11 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SAGE:
- SAGE Therapeutics’ Promising Parkinson’s Treatment Results
- Sage announces Phase 2 study of dalzanemdor did not meet primary endpoint
- Sage Therapeutics management to meet with Piper Sandler
- SAGE Therapeutics Board Member Announces Retirement
- Sage Therapeutics price target raised to $29 from $24 at JPMorgan
